Convelo Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $12M

  • Investors
  • 3

Convelo General Information

Description

Developer of stem cell based therapeutics designed to discover medicines for the regenerative capacity of the central nervous system. The company identifies novel drug candidates capable of directly stimulating oligodendrocyte progenitor cells to form new myelin and controls myelination, including defined drug-target, enabling medical researchers to regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 11000 Cedar Avenue
  • Cleveland, OH 44106
  • United States
+1 (216)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 11000 Cedar Avenue
  • Cleveland, OH 44106
  • United States
+1 (216)

Convelo Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Convelo Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 14-Nov-2024 $12M Completed Pre-Clinical Trials
5. Later Stage VC (Series B) 08-Dec-2022 Completed Clinical Trials - Phase 1
4. Secondary Transaction - Private 07-Dec-2020 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 25-Jul-2018 Completed Pre-Clinical Trials
2. Accelerator/Incubator $2M Completed Startup
1. Seed Round 05-Dec-2017 $2M $2M Completed Startup
To view Convelo’s complete valuation and funding history, request access »

Convelo Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 10,482,621 $0.000100 6% $0.75 $0.75 1x $0.75 21.58%
To view Convelo’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Convelo Patents

Convelo Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026112292-A1 Spirocyclic compounds for use in promoting remyelination Pending 20-Nov-2024
WO-2026015548-A1 Cyp51 inhibitors and method of using same Pending 08-Jul-2024
AU-2024334493-A1 Tertiary pyridyl amine modulators of cholesterol biosynthesis and their use for promoting remylination Pending 28-Aug-2023
EP-4770996-A1 Tertiary pyridyl amine modulators of cholesterol biosynthesis and their use for promoting remylination Pending 28-Aug-2023
WO-2025049495-A1 Tertiary pyridyl amine modulators of cholesterol biosynthesis and their use for promoting remylination Inactive 28-Aug-2023 C07D401/14
To view Convelo’s complete patent history, request access »

Convelo Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Convelo Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
JobsOhio Ventures Venture Capital Minority
Cleveland Convelo Holdings Corporation Minority
Jumpstart Ventures Venture Capital Minority
To view Convelo’s complete investors history, request access »

Convelo FAQs

  • When was Convelo founded?

    Convelo was founded in 2016.

  • Where is Convelo headquartered?

    Convelo is headquartered in Cleveland, OH.

  • What is the size of Convelo?

    Convelo has 11 total employees.

  • What industry is Convelo in?

    Convelo’s primary industry is Drug Discovery.

  • Is Convelo a private or public company?

    Convelo is a Private company.

  • What is the current valuation of Convelo?

    The current valuation of Convelo is .

  • What is Convelo’s current revenue?

    The current revenue for Convelo is .

  • How much funding has Convelo raised over time?

    Convelo has raised $32.6M.

  • Who are Convelo’s investors?

    JobsOhio Ventures, Cleveland Convelo Holdings, and Jumpstart Ventures have invested in Convelo.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process